Therapeutic drug level monitoring for mycophenolate mofetil: is it justified?
Stephan
A
A
Department of Transplantation and Nephrology, Rizk Hospital, Beirut, Lebanon.
Masri
M A
MA
Barbari
A
A
Kamel
G
G
Karam
A
A
Kilani
H
H
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods*; D017248:Enzyme Multiplied Immunoassay Technique; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012086:Reoperation / Q000706:statistics & numerical data
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D001379:Azathioprine